Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice

被引:56
作者
Pilarski, LM
Seeberger, K
Coupland, RW
Eshpeter, A
Keats, JJ
Taylor, BJ
Belch, AR
机构
[1] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[2] Univ Alberta, Dept Oncol, Edmonton, AB T6G 2M7, Canada
关键词
D O I
10.1016/S0301-472X(01)00788-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. In multiple myeloma (MM), the immunoglobulin gene rearrangement characterizing malignant plasma cells is unique. For a patient with multiple myeloma who underwent a B-cell leukemic blast transformation, using the immunoglobulin molecular signature, we characterized the clonal relationship to autologous plasma cells and the impact on normal polyclonal B-lymphocyte populations. Methods. Single-cell reverse transcriptase polymerase chain reaction (RT-PCR)/PCR was used to determine the clonal relationship between autologous MM plasma cells and leukemic B cells. A murine xenograft model was used to determine the myelomagenic potential of the leukemic B cells. Results. Single-cell analysis showed that circulating leukemic-phase cells were clonotypic, with an IgH VDJ sequence identical to that of diagnosis plasma cells. Analysis of IgH transcripts indicates MM clonal dominance over normal B-cell components of the immune system at diagnosis and during leukemic disease. Leukemic B cells were xenografted to irradiated NOD/SCID mice, leading to lytic bone lesions and clonotypic cells in murine BM. Although human cells in murine BM expressed CD138, a marker largely absent from ex vivo leukemic cells, the expression of CD45, CD19, and CD20 confirmed that engrafting cells were mature, probably late-stage B cells rather than plasma cells. Conclusions. Leukemic B cells are able to exert strong clonal dominance over normal components of the immune system, colonize the murine BM in a xenograft model, and disrupt normal bone metabolism leading to lytic bone lesions. This supports the hypothesis that clonotypic MM B cells are reservoirs of disease that persist throughout therapy and give rise to relapse. (C) 2002 International Society for Experimental Hematology. Published by Elsevier Science Inc.
引用
收藏
页码:221 / 228
页数:8
相关论文
共 30 条
[1]  
AGHAI E, 1988, ISRAEL J MED SCI, V24, P298
[2]  
AUBIN J, 1995, LEUKEMIA, V9, P471
[3]  
BAKKUS MHC, 1992, BLOOD, V80, P2326
[4]   EVIDENCE THAT THE CLONOGENIC CELL IN MULTIPLE-MYELOMA ORIGINATES FROM A PRE-SWITCHED BUT SOMATICALLY MUTATED B-CELL [J].
BAKKUS, MHC ;
VANRIET, I ;
VANCAMP, B ;
THIELEMANS, K .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 87 (01) :68-74
[5]  
BARTL R, 1989, EUR J HAEMATOL, V43, P88
[6]   IN MULTIPLE-MYELOMA, CLONOTYPIC B-LYMPHOCYTES ARE DETECTABLE AMONG CD19(+) PERIPHERAL-BLOOD CELLS EXPRESSING CD38, CD56, AND MONOTYPIC IG LIGHT-CHAIN [J].
BERGSAGEL, PL ;
SMITH, AM ;
SZCZEPEK, A ;
MANT, MJ ;
BELCH, AR ;
PILARSKI, LM .
BLOOD, 1995, 85 (02) :436-447
[7]   Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumor involvement [J].
Billadeau, D ;
Prosper, F ;
Verfaillie, C ;
Weisdorf, D ;
VanNess, B .
LEUKEMIA, 1997, 11 (09) :1565-1570
[8]  
BILLADEAU D, 1992, BLOOD, V80, P1818
[9]  
Billadeau D, 1996, BLOOD, V88, P289
[10]   THE BONE-MARROW OF MULTIPLE-MYELOMA PATIENTS CONTAINS B-CELL POPULATIONS AT DIFFERENT STAGES OF DIFFERENTIATION THAT ARE CLONALLY RELATED TO THE MALIGNANT PLASMA-CELL [J].
BILLADEAU, D ;
AHMANN, G ;
GREIPP, P ;
VANNESS, B .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (03) :1023-1031